{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:34:38Z","timestamp":1790757278645,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>People who inject drugs (PWID) are the most exposed to hepatitis C virus (HCV). In Thailand, drug use is highly criminalized, and harm reduction services are scarce. This study estimates risky injection practices and assesses the proportion of HCV awareness and screening in the PWID population in Northern Thailand.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used respondent-driven sampling (RDS) to recruit PWID in Chiang Mai Province. Social and behavioural data were collected through face-to-face interviews at an addiction treatment facility. Weighted population estimates were calculated to limit biases related to the non-random sampling method. Univariate and multivariate analyses were performed to study factors associated with HCV awareness and screening.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred seventy-one PWID were recruited between April 2016 and January 2017. Median age was 33 (Interquartile range: 26\u201340) years, 12.2% were women, and 49.4% belonged to a minority ethnic group. Among participants, 76.8% injected heroin, 20.7% methadone, and 20.7% methamphetamine. We estimate that 22.1% [95% CI: 15.7\u201328.6] of the population had shared needles in the last 6\u2009months and that 32.0% [95% CI: 23.6\u201340.4] had shared injection material. Only 26.6% [95% CI: 17.6\u201335.6] had heard of HCV. Factors independently associated with knowledge of HCV included belonging to a harm reduction organization (adjusted odds ratio (aOR)\u2009=\u20095.5 [95% CI: 2.0\u201315.3]) and voluntary participation in a drug rehabilitation programme (aOR\u2009=\u20094.3 [95% CI: 1.3\u201313.9]), while Lahu ethnicity was negatively associated (aOR\u2009=\u20090.3 [95% CI: 0.1\u20130.9]). We estimate that 5% of the PWID population were screened for HCV; the only factor independently associated with being screened was membership of a harm reduction organization (aOR\u2009=\u20095.7 [95% CI: 1.6\u201319.9]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study reveals that the PWID population is poorly informed and rarely screened for HCV, despite widespread risky injection practices. A public health approach aimed at reducing the incidence of HCV should target the PWID population and combine harm reduction measures with information and destigmatization campaigns. Civil society organizations working with PWID are a major asset for the success of such an approach, based on their current positive interventions promoting awareness of and screening for HCV.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-020-09549-w","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T12:02:47Z","timestamp":1600948967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Risky injection practices and HCV awareness in Chiang Mai Province, Thailand: a respondent-driven sampling study of people who inject drugs"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1505-6392","authenticated-orcid":false,"given":"Myrtille","family":"Prout\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Le Coeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9trey H.","family":"Tiv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timoth\u00e9e","family":"Dub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinya","family":"Jongpaijitsakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anantika","family":"Ratnamhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaisiri","family":"Angkurawaranon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apinun","family":"Aramrattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lallemant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"9549_CR1","volume-title":"Global hepatitis report, 2017","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Global hepatitis report, 2017; 2017."},{"key":"9549_CR2","volume-title":"Global health sector strategy on viral hepatitis 2016\u20132021: towards ending viral hepatitis","author":"World Health Organization (WHO)","year":"2016","unstructured":"World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016\u20132021: towards ending viral hepatitis; 2016."},{"issue":"9","key":"9549_CR3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","volume":"166","author":"O Falade-nwulia","year":"2018","unstructured":"Falade-nwulia O, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2018;166(9):637\u201348. https:\/\/doi.org\/10.7326\/M16-2575.","journal-title":"Ann Intern Med"},{"key":"9549_CR4","volume-title":"Progress report on HIV, viral hepatitis and sexually transmitted infections, 2019","author":"World Health Organization (WHO)","year":"2019","unstructured":"World Health Organization (WHO). Progress report on HIV, viral hepatitis and sexually transmitted infections, 2019; 2019."},{"issue":"7","key":"9549_CR5","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/cid\/ciu012","volume":"58","author":"A Hill","year":"2014","unstructured":"Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis. 2014;58(7):928\u201336. https:\/\/doi.org\/10.1093\/cid\/ciu012.","journal-title":"Clin Infect Dis"},{"key":"9549_CR6","volume-title":"Hepatitis C fact sheet","author":"WHO","year":"2018","unstructured":"WHO. Hepatitis C fact sheet; 2018. http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c (Accessed 28 Nov 2018)."},{"key":"9549_CR7","volume-title":"World drug report - booklet 3","author":"UNODC","year":"2018","unstructured":"UNODC. World drug report - booklet 3; 2018."},{"issue":"4","key":"9549_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.drugalcdep.2014.12.034","volume":"148","author":"D Prybylski","year":"2015","unstructured":"Prybylski D, et al. Diverse HIV epidemics among people who inject drugs in Thailand: evidence from respondent-driven sampling surveys in Bangkok and Chiang Mai. Drug Alcohol Depend. 2015;148(4):126\u201335. https:\/\/doi.org\/10.1016\/j.drugalcdep.2014.12.034.","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"9549_CR9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/aje\/kwn237","volume":"168","author":"H Hagan","year":"2008","unstructured":"Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis c virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008;168(10):1099\u2013109. https:\/\/doi.org\/10.1093\/aje\/kwn237.","journal-title":"Am J Epidemiol"},{"issue":"9","key":"9549_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2005","unstructured":"Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558\u201367. https:\/\/doi.org\/10.1016\/S1473-3099(05)70216-4.","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 2","key":"9549_CR11","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1093\/cid\/cit306","volume":"57","author":"EJ Aspinall","year":"2013","unstructured":"Aspinall EJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57(Suppl 2):S80\u20139. https:\/\/doi.org\/10.1093\/cid\/cit306.","journal-title":"Clin Infect Dis"},{"key":"9549_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.14562","volume-title":"Regional action plan for viral hepatitis in South-East Asia: 2016\u20132021","author":"World Health Organization (WHO)","year":"2017","unstructured":"World Health Organization (WHO), Regional Office for South-East Asia. Regional action plan for viral hepatitis in South-East Asia: 2016\u20132021; 2017. https:\/\/doi.org\/10.1111\/jpc.14562."},{"key":"9549_CR13","volume-title":"Thailand National strategy on viral hepatitis prevention and control, 2017\u20132021","author":"Ministry of Public Health","year":"2019","unstructured":"Ministry of Public Health. Thailand National strategy on viral hepatitis prevention and control, 2017\u20132021; 2019."},{"key":"9549_CR14","first-page":"119","volume-title":"Thailand\u2019s response to the HIV epidemic: yesterday, today, and tomorrow","author":"W Punpanich","year":"2004","unstructured":"Punpanich W, Ungchusak K, Detels R. Thailand\u2019s response to the HIV epidemic: yesterday, today, and tomorrow; 2004. p. 119\u201336."},{"issue":"34","key":"9549_CR15","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","volume":"22","author":"A Petruzziello","year":"2016","unstructured":"Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824. https:\/\/doi.org\/10.3748\/wjg.v22.i34.7824.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"9549_CR16","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1):S45\u201357. https:\/\/doi.org\/10.1016\/j.jhep.2014.07.027.","journal-title":"J Hepatol"},{"issue":"2","key":"9549_CR17","doi-asserted-by":"publisher","first-page":"e0149362","DOI":"10.1371\/journal.pone.0149362","volume":"11","author":"R Wasitthankasem","year":"2016","unstructured":"Wasitthankasem R, et al. Decreasing hepatitis C virus infection in Thailand in the past decade: evidence from the 2014 National Survey. PLoS One. 2016;11(2):e0149362. https:\/\/doi.org\/10.1371\/journal.pone.0149362.","journal-title":"PLoS One"},{"issue":"4","key":"9549_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0196301","volume":"13","author":"R Wasitthankasem","year":"2018","unstructured":"Wasitthankasem R, et al. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: implications for HCV elimination in the new therapeutic era, a population-based study. PLoS One. 2018;13(4):1\u201314. https:\/\/doi.org\/10.1371\/journal.pone.0196301.","journal-title":"PLoS One"},{"key":"9549_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2008\/840948","volume":"2008","author":"DJ Jamieson","year":"2008","unstructured":"Jamieson DJ, et al. Infection with hepatitis C virus among HIV-infected pregnant women in Thailand. Infect Dis Obstet Gynecol. 2008;2008:1\u20137. https:\/\/doi.org\/10.1155\/2008\/840948.","journal-title":"Infect Dis Obstet Gynecol"},{"issue":"Suppl 5","key":"9549_CR20","first-page":"S79","volume":"89","author":"T Tanwandee","year":"2006","unstructured":"Tanwandee T, Piratvisuth T, Phornphutkul K, Mairiang P, Permpikul P, Poovorawan Y. Risk factors of hepatitis C virus infection in blood donors in Thailand: a multicenter case-control study. J Med Assoc Thail. 2006;89(Suppl 5):S79\u201383 [Online]. Available: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17722300.","journal-title":"J Med Assoc Thail"},{"key":"9549_CR21","volume-title":"Using the multiplier methods to estimate the population size of injecting drug users (IDUs) in Thailand","author":"Aramrattana","year":"2011","unstructured":"Aramrattana et al., \u201cUsing the multiplier methods to estimate the population size of injecting drug users (IDUs) in Thailand,\u201d 2011."},{"issue":"9","key":"9549_CR22","first-page":"S17","volume":"98","author":"M Kanato","year":"2015","unstructured":"Kanato M. Size estimation of injecting drug users through the network scale-up method in Thailand. J Med Assoc Thail. 2015;98(9):S17\u201324.","journal-title":"J Med Assoc Thail"},{"issue":"9651","key":"9549_CR23","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/S0140-6736(08)61311-2","volume":"372","author":"BM Mathers","year":"2008","unstructured":"Mathers BM, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(08)61311-2.","journal-title":"Lancet"},{"issue":"2","key":"9549_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/dar.12689","volume":"37","author":"C Angkurawaranon","year":"2018","unstructured":"Angkurawaranon C, et al. Trends in the use of illicit substances in Thailand: results from national household surveys. Drug Alcohol Rev. 2018;37(2):1\u20136. https:\/\/doi.org\/10.1111\/dar.12689.","journal-title":"Drug Alcohol Rev"},{"issue":"6","key":"9549_CR25","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.4269\/ajtmh.2006.74.1111","volume":"74","author":"J Jittiwutikarn","year":"2006","unstructured":"Jittiwutikarn J, et al. Hepatitis C infection among drug users in northern Thailand. Am J Trop Med Hyg. 2006;74(6):1111\u20136 [Online]. Available: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16760529.","journal-title":"Am J Trop Med Hyg"},{"key":"9549_CR26","doi-asserted-by":"publisher","first-page":"296958","DOI":"10.1155\/2014\/296958","volume":"2014","author":"JB Jackson","year":"2014","unstructured":"Jackson JB, et al. Prevalence and seroincidence of hepatitis B and hepatitis C infection in high risk people who inject drugs in China and Thailand. Hepat Res Treat. 2014;2014:296958. https:\/\/doi.org\/10.1155\/2014\/296958.","journal-title":"Hepat Res Treat"},{"issue":"1","key":"9549_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/2224-3151.255350","volume":"8","author":"M Martin","year":"2019","unstructured":"Martin M, et al. Hepatitis C virus infection among people who inject drugs in Bangkok, Thailand, 2005-2010. WHO South-East Asia J public Heal. 2019;8(1):50\u20135. https:\/\/doi.org\/10.4103\/2224-3151.255350.","journal-title":"WHO South-East Asia J public Heal"},{"key":"9549_CR28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","volume":"378","author":"PK Nelson","year":"2011","unstructured":"Nelson PK, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571\u201383. https:\/\/doi.org\/10.1016\/S0140-6736(11)61097-0.","journal-title":"Lancet"},{"key":"9549_CR29","doi-asserted-by":"crossref","unstructured":"Khampang R, et al. Uptake of HIV, Hepatitis B and Hepatitis C testing among injection drug users in Thailand. Int J Prev Treat Subst Use Disord. 2015;1(3\u20134):38\u201354.","DOI":"10.4038\/ijptsud.v1i3-4.7837"},{"issue":"5","key":"9549_CR30","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1097\/QAI.0b013e31820bb1e5","volume":"56","author":"K Hayashi","year":"2011","unstructured":"Hayashi K, et al. Low uptake of hepatitis C testing and high prevalence of risk behavior among HIV-positive injection drug users in Bangkok, Thailand. J Acquir Immune Defic Syndr. 2011;56(5) United States:e133\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"9549_CR31","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/pubmed\/fds105","volume":"35","author":"L Ti","year":"2013","unstructured":"Ti L, Kaplan K, Hayashi K, Suwannawong P, Wood E, Kerr T. Low rates of hepatitis C testing among people who inject drugs in Thailand: implications for peer-based interventions. J Public Health. 2013;35(4):578\u201384. https:\/\/doi.org\/10.1093\/pubmed\/fds105.","journal-title":"J Public Health"},{"issue":"3","key":"9549_CR32","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1093\/pubmed\/fdv143","volume":"38","author":"AJ Heath","year":"2016","unstructured":"Heath AJ, et al. Healthcare avoidance by people who inject drugs in Bangkok, Thailand. J Public Health. 2016;38(3):e301\u20138. https:\/\/doi.org\/10.1093\/pubmed\/fdv143.","journal-title":"J Public Health"},{"key":"9549_CR33","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/1471-2458-9-492","volume":"9","author":"K Hayashi","year":"2009","unstructured":"Hayashi K, et al. Incarceration experiences among a community-recruited sample of injection drug users in Bangkok, Thailand. BMC Public Health. 2009;9:492. https:\/\/doi.org\/10.1186\/1471-2458-9-492.","journal-title":"BMC Public Health"},{"key":"9549_CR34","unstructured":"Human Rights Watch. Thailand\u2019s \u2018war on drugs; 2008. https:\/\/www.hrw.org\/news\/2008\/03\/12\/thailands-war-drugs. Accessed 26 June 2017."},{"key":"9549_CR35","doi-asserted-by":"publisher","unstructured":"Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmateer N, Taylor A, Bruneau J, Hickman M. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;9(9):CD012021. https:\/\/doi.org\/10.1002\/14651858.CD012021.pub2.","DOI":"10.1002\/14651858.CD012021.pub2"},{"issue":"1","key":"9549_CR36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/ije\/dyt243","volume":"43","author":"EJ Aspinall","year":"2014","unstructured":"Aspinall EJ, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):235\u201348. https:\/\/doi.org\/10.1093\/ije\/dyt243.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"9549_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1471-2458-13-53","volume":"13","author":"DC Des Jarlais","year":"2013","unstructured":"Des Jarlais DC, Feelemyer JP, Modi SN, Abdul-Quader A, Hagan H. High coverage needle\/syringe programs for people who inject drugs in low and middle income countries: a systematic review. BMC Public Health. 2013;13(1):53. https:\/\/doi.org\/10.1186\/1471-2458-13-53.","journal-title":"BMC Public Health"},{"issue":"2","key":"9549_CR38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1465-3362.2009.00093.x","volume":"29","author":"T Kerr","year":"2010","unstructured":"Kerr T, et al. Difficulty accessing syringes and syringe borrowing among injection drug users in Bangkok, Thailand. Drug Alcohol Rev. 2010;29(2):157\u201361. https:\/\/doi.org\/10.1111\/j.1465-3362.2009.00093.x.","journal-title":"Drug Alcohol Rev"},{"key":"9549_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-015-0050-5","volume":"12","author":"P Voon","year":"2015","unstructured":"Voon P, et al. High prevalence of syringe lending among HIV-positive people who inject drugs in Bangkok, Thailand. Harm Reduct J. 2015;12:1\u20135. https:\/\/doi.org\/10.1186\/s12954-015-0050-5.","journal-title":"Harm Reduct J"},{"key":"9549_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-99347-8_3","volume-title":"Global state of harm reduction 2018 - regional overview Asia","author":"M Alam","year":"2019","unstructured":"Alam M, Sawhney P. Global state of harm reduction 2018 - regional overview Asia; 2019. https:\/\/doi.org\/10.1007\/978-3-319-99347-8_3."},{"issue":"1","key":"9549_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-017-0189-3","volume":"14","author":"K Hayashi","year":"2017","unstructured":"Hayashi K, et al. Barriers to retention in methadone maintenance therapy among people who inject drugs in Bangkok, Thailand: a mixed-methods study. Harm Reduct J. 2017;14(1):1\u20138. https:\/\/doi.org\/10.1186\/s12954-017-0189-3.","journal-title":"Harm Reduct J"},{"issue":"1","key":"9549_CR42","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jsat.2011.10.022","volume":"43","author":"N Fairbairn","year":"2012","unstructured":"Fairbairn N, et al. Factors associated with methadone treatment among injection drug users in Bangkok, Thailand. J Subst Abus Treat. 2012;43(1):108\u201313. https:\/\/doi.org\/10.1016\/j.jsat.2011.10.022.","journal-title":"J Subst Abus Treat"},{"issue":"1","key":"9549_CR43","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugpo.2014.08.009","volume":"26","author":"K Hayashi","year":"2015","unstructured":"Hayashi K, Ti L, Kaplan K, Suwannawong P, Wood E, Kerr T. Police interference with methadone treatment in Bangkok, Thailand. Int J Drug Policy. 2015;26(1):112\u20135. https:\/\/doi.org\/10.1016\/j.drugpo.2014.08.009.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"9549_CR44","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/dar.12268","volume":"34","author":"R Khampang","year":"2015","unstructured":"Khampang R, Assanangkornchai S, Teerawattananon Y. Perceived barriers to utilise methadone maintenance therapy among male injection drug users in rural areas of southern Thailand. Drug Alcohol Rev. 2015;34(6):645\u201353. https:\/\/doi.org\/10.1111\/dar.12268.","journal-title":"Drug Alcohol Rev"},{"key":"9549_CR45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/01.aids.0000111386.02002.c6","volume":"2003","author":"S Vanichseni","year":"2004","unstructured":"Vanichseni S, Tappero JW, Pitisuttithum P, Kitayaporn D, Mastro TD, Vimutisunthorn E. Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX B \/ E HIV vaccine trial, Bangkok, Thailand. Aids. 2004;2003:311\u20136. https:\/\/doi.org\/10.1097\/01.aids.0000111386.02002.c6.","journal-title":"Aids"},{"key":"9549_CR46","doi-asserted-by":"publisher","unstructured":"Martin M, et al. Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir study, Thailand. PLoS One. 2011;6(9):1\u20137. https:\/\/doi.org\/10.1371\/journal.pone.0025127.","DOI":"10.1371\/journal.pone.0025127"},{"issue":"5","key":"9549_CR47","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3109\/10826084.2012.644110","volume":"47","author":"K Hayashi","year":"2012","unstructured":"Hayashi K, Fairbairn N, Suwannawong P, Kaplan K, Wood E, Kerr T. Collective empowerment while creating knowledge: a description of a community-based participatory research project with drug users in Bangkok, Thailand. Subst Use Misuse. 2012;47(5):502\u201310. https:\/\/doi.org\/10.3109\/10826084.2012.644110.","journal-title":"Subst Use Misuse"},{"issue":"2\u20133","key":"9549_CR48","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.drugalcdep.2007.03.013","volume":"90","author":"W Wattana","year":"2007","unstructured":"Wattana W, et al. Respondent-driven sampling to assess characteristics and estimate the number of injection drug users in Bangkok, Thailand. Drug Alcohol Depend. 2007;90(2\u20133):228\u201333. https:\/\/doi.org\/10.1016\/j.drugalcdep.2007.03.013.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"9549_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7748\/nr2013.01.20.3.33.c9495","volume":"20","author":"A Sydor","year":"2013","unstructured":"Sydor A. Conducting research into hidden or hard-to-reach populations. Nurs Res. 2013;20(3):33\u20137. https:\/\/doi.org\/10.7748\/nr2013.01.20.3.33.c9495.","journal-title":"Nurs Res"},{"issue":"2","key":"9549_CR50","doi-asserted-by":"publisher","first-page":"174","DOI":"10.2307\/3096941","volume":"44","author":"DD Heckathorn","year":"1997","unstructured":"Heckathorn DD. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl. 1997;44(2):174\u201399 Accessed: Mar. 07, 2014. [Online]. Available: http:\/\/cat.inist.fr\/?aModele=afficheN&cpsidt=2870723.","journal-title":"Soc Probl"},{"issue":"1","key":"9549_CR51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1525\/sp.2002.49.1.11","volume":"49","author":"DD Heckathorn","year":"2002","unstructured":"Heckathorn DD. Respondent-driven sampling II: deriving valid population estimates from chain-referral samples of hidden populations. Soc Probl. 2002;49(1):11\u201334 [Online]. Available: www.homelesshub.ca\/resource\/respondent-driven-sampling-ii-deriving-valid-population-estimates-chain-referral-samples.","journal-title":"Soc Probl"},{"issue":"4","key":"9549_CR52","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10461-012-0147-8","volume":"16","author":"C Wejnert","year":"2012","unstructured":"Wejnert C, Pham H, Krishna N, Le B, DiNenno E. Estimating design effect and calculating sample size for respondent-driven sampling studies of injection drug users in the United States. AIDS Behav. 2012;16(4):797\u2013806. https:\/\/doi.org\/10.1007\/s10461-012-0147-8.","journal-title":"AIDS Behav"},{"key":"9549_CR53","unstructured":"WHO\/UNAIDS. Introduction to HIV\/AIDS and sexually transmitted infection surveillance: Module 4: Introduction to Respondent Driven Sampling. Geneva; 2013."},{"issue":"7","key":"9549_CR54","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1007\/s10461-017-1827-1","volume":"22","author":"J Li","year":"2018","unstructured":"Li J, et al. Overlooked threats to respondent driven sampling estimators: peer recruitment reality, degree measures, and random selection assumption. AIDS Behav. Jul. 2018;22(7):2340\u201359. https:\/\/doi.org\/10.1007\/s10461-017-1827-1.","journal-title":"AIDS Behav"},{"issue":"1","key":"9549_CR55","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/rssa.12059","volume":"178","author":"KJ Gile","year":"2015","unstructured":"Gile KJ, Johnston LG, Salganik MJ. Diagnostics for respondent-driven sampling. J R Stat Soc Ser A Stat Soc. 2015;178(1):241\u201369. https:\/\/doi.org\/10.1111\/rssa.12059.","journal-title":"J R Stat Soc Ser A Stat Soc"},{"issue":"493","key":"9549_CR56","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1198\/jasa.2011.ap09475","volume":"106","author":"KJ Gile","year":"2011","unstructured":"Gile KJ. Improved inference for respondent-driven sampling data with application to HIV prevalence estimation. J Am Stat Assoc. 2011;106(493):135\u201346. https:\/\/doi.org\/10.1198\/jasa.2011.ap09475.","journal-title":"J Am Stat Assoc"},{"key":"9549_CR57","volume-title":"Mind the gap: HCV policies versus community experiences","author":"Coalition Plus","year":"2018","unstructured":"Coalition Plus. Mind the gap: HCV policies versus community experiences; 2018."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-09549-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-020-09549-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-09549-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T02:16:41Z","timestamp":1632449801000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-020-09549-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9549"],"URL":"https:\/\/doi.org\/10.1186\/s12889-020-09549-w","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]},"assertion":[{"value":"11 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol received ethical clearance on 16 February 2016 from the ethics committee of the Faculty of Associated Medical Science, Chiang Mai University (project code AMSEC-59FB-005). The study was conducted in compliance with the latest version of the Helsinki declaration on the ethical principles applicable to medical research on human subjects. Written informed consent was obtained for each participant before data collection. Respondents were informed that their answers would remain strictly confidential, that their participation was voluntary, and that they could withdraw from the study at any time without explanation and without negative repercussions.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1450"}}